Psychometric Comparison of the Standard EQ-5D to a 5 Level Version in Cancer Patients

Abstract

Evidence supported the validity of both EQ-5D-3L and EQ-5D-5L in cancer. However, results suggest a 5-level classifier system has less ceiling effect and greater discriminative ability with potentially more power to detect differences between groups compared with EQ-5D-3L.

The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty

“…The original EQ-5D-3L is a brief survey but its sensitivity to change has been questioned [2,12,13,15,19]. The new EQ-5D-5L survey has been validated in several patient populations for improving the sensitivity of HRQoL measurements [8,10,11,16,18], but has yet to be validated in a THA population. Our work suggests that with the addition of two response options, the five-level survey may be able to better measure change in HRQoL after surgery.…”

“…Our patient populations had some higher rates of inconsistent responses in certain dimensions than seen in other EQ-5D-5L survey test populations [10,11,16,18]. Unlike our method, the most common technique in the literature for comparing the three-and five-level surveys was to administer both surveys with demographic and additional survey questions in between the two versions during the same sitting [4,10,11,16,18].…”

“…Unlike our method, the most common technique in the literature for comparing the three-and five-level surveys was to administer both surveys with demographic and additional survey questions in between the two versions during the same sitting [4,10,11,16,18]. As was seen by Janssen and collaborators [9] in 2008, this simultaneous administration of survey versions actually influenced patient responses leading to patients avoiding intermediate response options on the five-level survey if the three-level had been administered first.…”

“…The five-level EQ-5D survey has been shown to have face validity, decrease ceiling effects, and increase discriminatory power in several patient populations over the three-level version [8,10,11,16,18]. However, the validity of this version has not, to our knowledge, been evaluated in patients undergoing THA.…”

EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study (Preprint)

“…The new EQ-5D-5L has already been tested in some disease-specific samples, such as patients with cancer [20,21] and with hepatitis [22], showing a better discrimination capability and lower ceiling effects than the traditional 3-level version (11% vs 17% [20], 9.7% vs 16.8% [21], and 21.6% vs 38.3% [22].) However, to date, there are neither studies assessing the new 5-level version when administered via the internet, nor studies evaluating its metric properties in asthma patients.…”